TriSalus Life Sciences (TLSI) Income from Continuing Operations (2021 - 2026)

TriSalus Life Sciences has reported Income from Continuing Operations for 6 years, with the latest figure at 1539000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 114.83% year-over-year to 1539000.0; the trailing twelve-month figure through Mar 2026 stood at 27313000.0 (changed 0.36% YoY), and the FY2025 full-year result was 39227000.0, down 30.56% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 1539000.0, up from 9753000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 2836725.0 in Q1 2022, with the low at 35639000.0 in Q4 2023.
• Historically, Income from Continuing Operations has averaged 8967708.0 across 5 years, with a median of 8288000.0 in 2025.
• The largest YoY upside for Income from Continuing Operations was 1137.69% in 2022 against a maximum downside of 878.46% in 2022.
• TriSalus Life Sciences' Income from Continuing Operations stood at 22542000.0 in 2022, then tumbled by 58.1% to 35639000.0 in 2023, then soared by 71.64% to 10108000.0 in 2024, then gained by 3.51% to 9753000.0 in 2025, then surged by 115.78% to 1539000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 1539000.0 (Q1 2026), 9753000.0 (Q4 2025), and 10811000.0 (Q3 2025), per Business Quant data.